Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Triplet Might Offer Arcus An Edge

Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet

Arcus Biosciences
Founded in 2015, Arcus is hoping anti-TIGIT candidate domvanalimab will be its big breakthrough. • Source: Alamy

Arcus Biosciences has presented early Phase II data on its TIGIT inhibitor, domvanalimab, but partner Gilead Sciences, Inc. is not yet committing to funding pivotal studies, even as an interim analyses, particularly of a triplet combination, give encouraging hints of efficacy.

TIGIT inhibitors are a promising new avenue in immuno-oncology therapy, and Arcus is in the race to bring the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip